Sr 786

Five previously characterized NPM‐ALK⁺ T‐cell lymphoma cell lines: Karpas 299, SR‐786, SU‐DHL‐1, SUP‐M2, and DEL (DSMZ, Braunschweig, Germany), were used in the study (Drexler, 2010). The breast cancer cell line MCF7 and neuroblastoma cell line SK‐N‐AS (ATCC, Manassas, VA, USA) were used as positive controls for the expression of NGF and TrkA, respectively. Human peripheral blood CD3⁺ pan‐T lymphocytes were purchased from StemCell Technologies (catalog number: 70024; Vancouver, BC, Canada). The ALK inhibitor ASP3026 (CT‐ASP302; ChemieTek, Indianapolis, IN, USA) was dissolved in DMSO mixed with H₂O and HCl (1 : 1).
Cells were maintained in RPMI‐1640 medium (NPM‐ALK⁺ lymphoma cell lines) or Dulbecco's modified Eagle's medium (MCF7, SK‐N‐AS) (Thermo Fisher Scientific, Waltham, MA, USA), supplemented with 10% heat‐inactivated fetal bovine serum (FBS), penicillin (100 U·mL⁻¹), streptomycin (100 μg·mL⁻¹), and l‐glutamine (2 mm) (all from Sigma Aldrich, St. Louis, MO, USA). Cell cultures were maintained at 37 °C in humidified air with 5% CO₂. In some experiments, cells were cultured overnight in 0.5–1% FBS. Then, 250 or 500 ng·mL⁻¹ recombinant human β‐NGF (256‐GF‐100/CF; R&D Systems, Minneapolis, MN, USA) was added with or without 5 μg·mL⁻¹ anti‐TrkA‐neutralizing antibody (AF175; R&D Systems).

The NPM-ALK⁺ T cell lymphoma cell lines Karpas 299, DEL, and SR-786 were purchased from DSMZ (Braunschweig, Germany). Cells were maintained in RPMI 1640 plus 10% FBS, 2 mM glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin, in a humidified chamber at 37 °C with 5% CO₂.